Value Investing Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: paulelgin who wrote (51401)	4/24/2013 6:01:03 AM
From: Ditchdigger	Read Replies (1) of 78661

"PegIntron is BY FAR the most important of the royalty-generating drugs" and there in lies a problem. The holy grail of Hep C treatment is to eliminate peg- interferon from the current cocktail(s) being used--and it appears that isn't to far off in the future (beginning with geno 1's). New treatment time has already been cut in half for many to 24 weeks, compared to 48 minimum in the past. While the number of hep c cases is increasing,the market for pegintron and it's competitor pegasys (both requiring injection) has a target on it's back. blogs.marketwatch.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next